



## Clinical trial results:

**Clinical study to evaluate the safety and tolerability of immunoglobulin intravenous (human) 10% (NewGam) administered at high infusion rates to patients with primary immunodeficiency diseases (extension of study NGAM-01)**

### Summary

EudraCT number	2011-005015-82
Trial protocol	Outside EU/EEA
Global end of trial date	26 September 2012

### Results information

Result version number	v1 (current)
This version publication date	30 November 2016
First version publication date	30 November 2016

### Trial information

#### Trial identification

Sponsor protocol code	NGAM-05
-----------------------	---------

#### Additional study identifiers

ISRCTN number	ISRCTN11002924
ClinicalTrials.gov id (NCT number)	NCT01313507
WHO universal trial number (UTN)	-

Notes:

### Sponsors

Sponsor organisation name	Octapharma AG
Sponsor organisation address	Seidenstrasse 2, Lachen, Switzerland, CH-8853
Public contact	Clinical Research Department, Octapharma Pharmazeutika Produktionsgesellschaft mbH, 0043 1 61032 1202, barbara.pyringer@octapharma.com
Scientific contact	Clinical Research Department, Octapharma Pharmazeutika Produktionsgesellschaft mbH, 0043 1 61032 1202, barbara.pyringer@octapharma.com

Notes:

### Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	Yes
EMA paediatric investigation plan number(s)	EMA-001110-PIP01-10
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

---

**Results analysis stage**

---

Analysis stage	Final
Date of interim/final analysis	31 July 2013
Is this the analysis of the primary completion data?	No

Global end of trial reached?	Yes
Global end of trial date	26 September 2012
Was the trial ended prematurely?	No

Notes:

---

**General information about the trial**

---

Main objective of the trial:

To assess the safety and tolerability of NewGam when administered at infusion rates from 0.08 mL/kg/min (the maximum rate in study NGAM-01) to 0.14 mL/kg/min.

Protection of trial subjects:

This trial was conducted in accordance to the principles of GCP, ensuring that the rights, safety and well-being of patients are protected and in consistency with the Declaration of Helsinki. Inclusion and exclusion criteria were carefully defined in order to protect subjects from contraindications, interactions with other medication and risk factors associated with the investigational medicinal product. Throughout the study safety was assessed, such as occurrence of AEs, safety labs, vital signs and physical examinations.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	05 May 2011
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	Yes

Notes:

---

**Population of trial subjects**

---

**Subjects enrolled per country**

Country: Number of subjects enrolled	United States: 21
Worldwide total number of subjects	21
EEA total number of subjects	0

Notes:

---

**Subjects enrolled per age group**

---

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	8
Adolescents (12-17 years)	5
Adults (18-64 years)	8
From 65 to 84 years	0

85 years and over	0
-------------------	---

## Subject disposition

### Recruitment

Recruitment details:

Patients were taken exclusively from the cohort of patients who had completed the study NGAM-01 and had received NewGam at the maximum infusion rate of 0.08 mL/kg/min without the need for premedication at least for the last three infusions, without restrictions as regards to age group or treatment regimen.

### Pre-assignment

Screening details:

Screening had to be performed at the follow-up visit of the NGAM-01 study.

### Period 1

Period 1 title	overall trial (overall period)
Is this the baseline period?	Yes
Allocation method	Not applicable
Blinding used	Not blinded

### Arms

Arm title	NewGam
-----------	--------

Arm description:

Patients received 200 to 800 mg/kg body weight every 21 ( $\pm$  3) days or 28 ( $\pm$  3) days for 3 months, with individual doses and intervals being dependent on the patient's previous dosing in the NGAM-01 study. Therefore, each patient received either five infusions (at 3-week intervals) or four infusions (at 4-week intervals) of NewGam.

Arm type	Experimental
Investigational medicinal product name	NewGam, human normal immunoglobulin 10%, solvent/detergent treated solution for intravenous infusion
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:

The range of doses to be infused was 200 to 800 mg/kg body weight every 21 ( $\pm$  3) days or 28 ( $\pm$  3) days, with individual doses and intervals being dependent on the patient's previous dosing in the NGAM-01 study.

<b>Number of subjects in period 1</b>	NewGam
Started	21
Completed	21

## Baseline characteristics

### Reporting groups

Reporting group title	overall trial
-----------------------	---------------

Reporting group description:

All patients who received at least one dose of NewGam in the context of this study.

Reporting group values	overall trial	Total	
Number of subjects	21	21	
Age categorical			
Units: Subjects			
Children ≥2 Years <12 Years	8	8	
Adolescents ≥12 Years <16	3	3	
Adults ≥16 Years ≤75 Years	10	10	
Age continuous			
Units: years			
arithmetic mean	23.8		
standard deviation	± 19.78	-	
Gender categorical			
Units: Subjects			
Female	8	8	
Male	13	13	

## End points

### End points reporting groups

Reporting group title	NewGam
Reporting group description: Patients received 200 to 800 mg/kg body weight every 21 ( $\pm$ 3) days or 28 ( $\pm$ 3) days for 3 months, with individual doses and intervals being dependent on the patient's previous dosing in the NGAM-01 study. Therefore, each patient received either five infusions (at 3-week intervals) or four infusions (at 4-week intervals) of NewGam.	

### Primary: Percentage of Participants Who Experienced at Least 1 Adverse Event Causally Related to the Administration of the Study Drug

End point title	Percentage of Participants Who Experienced at Least 1 Adverse Event Causally Related to the Administration of the Study Drug <sup>[1]</sup>
-----------------	---

End point description:

An adverse event was considered to be causally related to the administration of the study drug if it judged to be probably or possibly related to the study drug, as assessed by the investigator

End point type	Primary
----------------	---------

End point timeframe:

Baseline to the end of the study

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: parameters were presented in descriptive statistics.

End point values	NewGam			
Subject group type	Reporting group			
Number of subjects analysed	21			
Units: percentage of patients				
number (not applicable)	19			

### Statistical analyses

No statistical analyses for this end point

### Primary: Percentage of Participants Who Experienced at Least 1 Adverse Event Temporally Related to the Study Drug

End point title	Percentage of Participants Who Experienced at Least 1 Adverse Event Temporally Related to the Study Drug <sup>[2]</sup>
-----------------	---

End point description:

An adverse event was considered to be temporally related to the study drug if it started during an infusion or within 72 hours after the end of an infusion.

End point type	Primary
----------------	---------

End point timeframe:

From Baseline to the end of the study

---

Notes:

[2] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: parameters were presented in descriptive statistics.

<b>End point values</b>	NewGam			
Subject group type	Reporting group			
Number of subjects analysed	21			
Units: percentage of participants				
number (not applicable)	38.1			

### Statistical analyses

---

No statistical analyses for this end point

## Adverse events

### Adverse events information

Timeframe for reporting adverse events:

AEs had to be reported from baseline to the end of the study.

Assessment type	Systematic
-----------------	------------

### Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	14.0
--------------------	------

### Reporting groups

Reporting group title	Safety Set
-----------------------	------------

Reporting group description:

The safety analysis set was the only study population that has been considered in the statistical data presentations. It is defined as all patients who received at least one dose of NewGam in the context of this study.

Serious adverse events	Safety Set		
Total subjects affected by serious adverse events			
subjects affected / exposed	0 / 21 (0.00%)		
number of deaths (all causes)	0		
number of deaths resulting from adverse events	0		

Frequency threshold for reporting non-serious adverse events: 5 %

Non-serious adverse events	Safety Set		
Total subjects affected by non-serious adverse events			
subjects affected / exposed	12 / 21 (57.14%)		
Injury, poisoning and procedural complications			
Contusion			
subjects affected / exposed	2 / 21 (9.52%)		
occurrences (all)	2		
Nervous system disorders			
Headache			
subjects affected / exposed	2 / 21 (9.52%)		
occurrences (all)	3		
General disorders and administration site conditions			



Chest pain subjects affected / exposed occurrences (all)	2 / 21 (9.52%) 2		
Pyrexia subjects affected / exposed occurrences (all)	2 / 21 (9.52%) 2		
Gastrointestinal disorders			
Nausea subjects affected / exposed occurrences (all)	3 / 21 (14.29%) 3		
Vomiting subjects affected / exposed occurrences (all)	3 / 21 (14.29%) 3		
Abdominal pain subjects affected / exposed occurrences (all)	2 / 21 (9.52%) 2		
Diarrhoea subjects affected / exposed occurrences (all)	2 / 21 (9.52%) 2		
Infections and infestations			
Sinusitis subjects affected / exposed occurrences (all)	4 / 21 (19.05%) 4		
Nasopharyngitis subjects affected / exposed occurrences (all)	2 / 21 (9.52%) 2		

## **More information**

### **Substantial protocol amendments (globally)**

Were there any global substantial amendments to the protocol? No

---

### **Interruptions (globally)**

Were there any global interruptions to the trial? No

### **Limitations and caveats**

None reported